Rejuvel Bio-Sciences, Inc.
NUUU
$0.00
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | 135.60% | 137.46% | 270.55% | 82.91% | 96.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 135.60% | 137.46% | 270.55% | 82.91% | 96.30% |
| Cost of Revenue | 229.43% | 210.53% | 268.72% | 210.82% | 243.68% |
| Gross Profit | 79.23% | 81.30% | 272.82% | -56.45% | 55.97% |
| SG&A Expenses | 95.22% | 130.19% | 54.56% | 25.90% | 42.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.80% | 134.06% | 63.66% | 34.39% | 46.30% |
| Operating Income | -96.45% | -133.63% | -46.41% | -29.71% | -41.86% |
| Income Before Tax | -43.17% | 48.39% | 161.41% | 50.68% | 2.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.17% | 48.39% | 161.41% | 50.68% | 2.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.17% | 48.39% | 161.41% | 50.68% | 2.65% |
| EBIT | -96.45% | -133.63% | -46.41% | -29.71% | -41.86% |
| EBITDA | -96.65% | -134.15% | -46.21% | -29.51% | -42.00% |
| EPS Basic | -226.98% | -36.96% | 157.26% | 80.33% | 1.56% |
| Normalized Basic EPS | -220.00% | -34.48% | 157.42% | 78.95% | 0.00% |
| EPS Diluted | -126.17% | 7.35% | 139.52% | 8.20% | -67.19% |
| Normalized Diluted EPS | -212.20% | -32.20% | 156.77% | 76.32% | -2.50% |
| Average Basic Shares Outstanding | -56.53% | -45.79% | -31.19% | -16.73% | -1.97% |
| Average Diluted Shares Outstanding | -56.65% | -45.92% | -30.92% | -16.46% | -1.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
